Manali Kamdar, MD, clinical director of lymphoma services, University of Colorado Cancer Center, Denver, Colorado, discusses the use of circulating tumor DNA as an early predictor of outcomes in patients with second-line large B-cell lymphoma treated with lisocabtagene maraleucel versus standard of care in the Phase 3 TRANSFORM trial. Dr Kamdar explains that low levels of baseline circulating tumor DNA were correlated with higher event-free survival, and patients who received lisocabtagene maraleucel had higher evidence of measurable residual disease negativity.